This ADC product is comprised of an anti-CDH1 monoclonal antibody conjugated via a linker to a PBD dimers. The PBD dimers is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, PBD dimers binds to DNA, causes DNA damage.
ADC Target
- Alternative Names
- CDH1; cadherin 1, type 1, E-cadherin (epithelial); UVO; CDHE; ECAD; LCAM; Arc-1; CD324; cadherin-1; CAM 120/80; E-Cadherin; uvomorulin; cell-CAM 120/80; epithelial cadherin; cadherin 1, E-cadherin (epithelial); calcium-dependent adhesion protein, epitheli
- Target Entrez Gene ID
- 999
- Overview
- This gene is a classical cadherin from the cadherin superfamily. The encoded protein is a calcium dependent cell-cell adhesion glycoprotein comprised of five extracellular cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail. Mutations in this gene are correlated with gastric, breast, colorectal, thyroid and ovarian cancer. Loss of function is thought to contribute to progression in cancer by increasing proliferation, invasion, and/or metastasis. The ectodomain of this protein mediates bacterial adhesion to mammalian cells and the cytoplasmic domain is required for internalization. Identified transcript variants arise from mutation at consensus splice sites.
ADC Antibody
- Overview
- Anti-CDH1 Antibody
ADC payload drug
- Name
- pyrrolobenzodiazepine (PBD) dimers
- Description
- Pyrrolobenzodiazepine (PBD) dimmers are highly cytotoxic DNA cross-linking agents. PBDs exert their biological activity through covalent binding via their N10-C11imine/carbinolamine moieties to the C2-amino position of a guanine residue within the minor groove of DNA.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products